Filing Flows › TherapeuticsMD (TXMD) › Q2 2025
TherapeuticsMD (TXMD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
TherapeuticsMD (TXMD) reported revenue of $952K for the second quarter 2025 (Q2 2025), +307% from a year earlier and +142% from the quarter before. Operating margin was -73.0%, net earnings $551K (57.9% of revenue).
TherapeuticsMD, Q2 2025: revenue $952K (+307% year over year), operating margin -73.0%, net earnings $551K, operating cash flow $381K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $952K | +142% | +307% |
| Operating profit | −$695K | — | — |
| Net earnings | $551K | — | — |
| Operating cash flow | $381K | -45% | -74% |
What changed
Revenue was $1.0M in Q2 2025, up 307% year over year and up 142% from the previous quarter.
Operating costs exceeded revenue by $695K, an operating margin of -73.0%. Total costs fell 46% while revenue rose 307%. Net earnings were $551K. The effective tax rate was 0.0%. Non-operating items added $1.2M, 226% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $381K (down 74% year over year), 69% of net earnings. Non-cash charges added back $96K of depreciation and amortization and $1K of share-based compensation. Working capital and other items used $267K.
Questions
What was TherapeuticsMD's revenue in the second quarter 2025?
TherapeuticsMD (TXMD) reported revenue of $952K for the second quarter 2025 (Q2 2025), +307% from a year earlier and +142% from the quarter before.
Was TherapeuticsMD profitable in the second quarter 2025?
Operating loss was $695K (-73.0% of revenue) and net earnings $551K.
Source: TherapeuticsMD 10-Q on SEC EDGAR.